AIM ImmunoTech Email Formats

Pharmaceutical Manufacturing • Marion Oaks, Florida, United States • 21-50 Employees

AIM ImmunoTech Email Formats

AIM ImmunoTech uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@aimimmuno.com), used 64.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@aimimmuno.com	64.7%
{first name}.{last name}	john.doe@aimimmuno.com	35.3%

Key Contacts at AIM ImmunoTech

David Chemerow

Member Board Of Directors

Jodie Pelz

Director Of Accounting & Finance

Peter Rodino

Chief Operating Officer, General Counsel And Executive Director Of Governmental Relations

Sophia Johnson

Director Of Operations

Ann Marie E. Coverly

Director Of Human Resources And Administration; Deputy Investor Relations Coordinator

Tom Equels

Chief Executive Officer

Company overview

Headquarters	2117 SW Highway 484, Ocala, FL 34473, US
Phone number	+19088240775
Websites	aimimmuno.com jtcir.com hemispherx.net
NAICS	3254
SIC	514
Employees	21-50
Socials

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.